Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.73 |
| ▸ | PDE4A | P27815 | 11/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.73 |
| ▸ | PDE5A | O76074 | 4/20 | 0.57 |
| ▸ | PDE1A | P54750 | 2/20 | 0.57 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.57 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7333023 | 0.91 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7361781 | 0.88 | PDE4D (0.57) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7337204 | 0.87 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7335169 | 0.87 | PDE4D (0.83) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7334025 | 0.86 | PDE4D (0.82) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL71154 | 0.85 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL71231 | 0.85 | PDE4D (0.77) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL71788 | 0.85 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7338641 | 0.84 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL71065 | 0.84 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | claimed |
| EP-0497564-B1 | Benzamides | RHONE POULENC RORER LTD (GB) | 1995-12-27 | — | — | EP | claimed |
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0497564-B1 | Benzamides | RHONE POULENC RORER LTD (GB) | 1995-12-27 | — | — | EP | disclosed |
| EP-0669311-A1 | Benzamides | RHONE POULENC RORER LIMITED (GB) | 1995-08-30 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| EP-0569414-A1 | BENZAMIDES | RHONE-POULENC RORER LIMITED (GB) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012961-A1 | BENZAMIDES | RHONE POULENC RORER LIMITED (GB) | 1992-08-06 | — | — | WO | disclosed |
| EP-0497564-A1 | Benzamides | RHONE POULENC RORER LIMITED (GB) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 7/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.